Hepatitis B and C in the liver transplant recipient: current understanding and treatment (Q34426421)

2 August 2017

1 reference

title

Hepatitis B and C in the liver transplant recipient: current understanding and treatment (English)

1 reference

2 August 2017

1 reference

H R Rosen

1

1 reference

2 August 2017

1 November 2001

1 reference

2 August 2017

Liver Transplantation

1 reference

2 August 2017

7

1 reference

2 August 2017

11 Suppl 1

1 reference

2 August 2017

S87-98

1 reference

Hepatitis B and C in the liver transplant recipient

2 August 2017

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Modulation of the immunological response to hepatitis B virus by antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Morphological spectrum of polyoma virus disease in renal allografts: diagnostic accuracy of urine cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Posttransplantation prevention and treatment of recurrent hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Hepatitis B virus mutations in the pre-S genome before and after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Liver transplantation: current status and novel approaches to liver replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

A longitudinal analysis of hepatitis C virus replication following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Hepatitis C infection in patients undergoing liver retransplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Retransplantation for hepatitis C: implications of different policies

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.28519

21 January 2018

Identifiers

DOI

10.1053/JLTS.2001.28519

1 reference

release_3bwx7weq4bdtvl7eit5zyvw2km

2 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3bwx7weq4bdtvl7eit5zyvw2km

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

11689781

1 reference

PubMed ID

11689781